Marinomed is led by a strong management team with expertise in virology and infectious diseases, allergy and immunology, assay technology and molecular biology. The team combines this expertise with an extensive background in product development for biopharmaceutical and pharmaceutical companies.
Dr. Grassauer is co-founder of Marinomed. He has a degree in virology and is co-inventor of several key patents in the field of virology, including the patents protecting the MAVIREX technology platform. He is particularly experienced in the establishment and development of high-tech companies.
Dr. Prieschl-Grassauer has more than ten years of experience working in pharmaceutical drug development. Before Marinomed, she was head of the allergy program at Novartis in Vienna. In this position, she discovered the mechanism of action of FTY720 (Fingolimod), Novartis´ novel immunomodulatory drug against multiple sclerosis. Following that, she supervised the clinical development of an innovative cancer therapy drug that was in clinical Phase III. Dr. Prieschl-Grassauer has published more than 30 articles in high ranking peer-reviewed journals in the field of immunology, molecular biology and medicinal chemistry.
Dr. Bodenteich joined Marinomed from onepharm Research & Development, where she held the position of Chief Medical Officer for the last two years and Head Development for one year prior to that. Her main responsibilities in these positions included designing and conducting clinical trials, building partnerships with research institutions and general business development activities. She also spent four years at Sanochemia Pharmazeutika AG as Head of Research & Development, where she was responsible for both pharmaceutical and business development. Dr. Bodenteich has more than 15 years of experience in the pharmaceutical industry, she is a trained pathologist who held positions in research and industry in Austria, Norway and in the USA.